Literature DB >> 21068695

Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID.

Jeanne M Marrazzo1, David H Martin, D Heather Watts, Joann Schulte, Jack D Sobel, Sharon L Hillier, Carolyn Deal, David N Fredricks.   

Abstract

The microbiota of the human vagina can affect the health of women, their fetuses, and newborns. Bacterial vaginosis (BV) is the most prevalent form of vaginal infection in women of reproductive age, affecting 8% to 23%, and is the most common etiology of vaginal symptoms prompting women to seek medical care. While traditional cultivation has identified numerous BV-associated bacteria involved in these processes, recent advances in molecular biology have facilitated the detection and identification of bacteria without cultivation, some of which have not previously been described or well characterized. A more complete understanding of vaginal microbial populations resulting from the adoption of molecular tools may lead to better strategies to maintain healthy vaginal microbial communities-thus enhancing women's health-and will create opportunities to explore the role of novel bacteria in reproductive tract diseases. On November 19-20, 2008, the NIH convened a workshop of experts in the field of research and clinical practice related to BV in order to discuss how these new advances should be interpreted and applied to research in progress and collaborations between relevant disciplines. This paper summarizes the presentations of this workshop and outlines general recommendations arising from the related discussions. Future studies of BV and its associated adverse outcomes should determine if specific combinations of organisms are more pathogenic than others, and causally associated with different adverse events. Moreover, determination of causality will depend not only on more precise categorization of the vaginal microbiota, but also on variations in the host environment that may be associated with changes in bacterial communities over time. In this report, we offer suggestions and recommendations that we hope will facilitate conduct of consistent approaches to collaborative efforts towards advancing our understanding of the vaginal microbiota and its impact on human health.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068695      PMCID: PMC3137891          DOI: 10.1097/OLQ.0b013e3181fbbc95

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  79 in total

1.  Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.

Authors:  Jack D Sobel; Daron Ferris; Jane Schwebke; Paul Nyirjesy; Harold C Wiesenfeld; Jeffrey Peipert; David Soper; Suzanne E Ohmit; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

2.  Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.

Authors:  J M Baeten; P M Nyange; B A Richardson; L Lavreys; B Chohan; H L Martin; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss
Journal:  Am J Obstet Gynecol       Date:  2001-08       Impact factor: 8.661

3.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

4.  Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease.

Authors:  Mark H Yudin; Sharon L Hillier; Harold C Wiesenfeld; Marijane A Krohn; Antonio A Amortegui; Richard L Sweet
Journal:  Am J Obstet Gynecol       Date:  2003-02       Impact factor: 8.661

5.  Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection.

Authors:  Harold C Wiesenfeld; Sharon L Hillier; Marijane A Krohn; Daniel V Landers; Richard L Sweet
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

6.  High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.

Authors:  Catriona S Bradshaw; Anna N Morton; Jane Hocking; Suzanne M Garland; Margaret B Morris; Lorna M Moss; Leonie B Horvath; Irene Kuzevska; Christopher K Fairley
Journal:  J Infect Dis       Date:  2006-04-26       Impact factor: 5.226

7.  Is bacterial vaginosis a sexually transmitted disease?

Authors:  P G Larsson; J J Platz-Christensen; E Sundström
Journal:  Int J STD AIDS       Date:  1991 Sep-Oct       Impact factor: 1.359

8.  Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods.

Authors:  Xia Zhou; Stephen J Bent; Maria G Schneider; Catherine C Davis; Mohammed R Islam; Larry J Forney
Journal:  Microbiology (Reading)       Date:  2004-08       Impact factor: 2.777

9.  Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group.

Authors:  S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao
Journal:  N Engl J Med       Date:  1995-12-28       Impact factor: 91.245

Review 10.  Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient.

Authors:  R L Sweet
Journal:  Infect Dis Obstet Gynecol       Date:  2000
View more
  52 in total

Review 1.  The microbiota of the vagina and its influence on women's health and disease.

Authors:  David H Martin
Journal:  Am J Med Sci       Date:  2012-01       Impact factor: 2.378

2.  Association between BVAB1 and high Nugent scores among women with bacterial vaginosis.

Authors:  Christina A Muzny; Imran R Sunesara; Michael E Griswold; Ranjit Kumar; Elliot J Lefkowitz; Leandro A Mena; Jane R Schwebke; David H Martin; Edwin Swiatlo
Journal:  Diagn Microbiol Infect Dis       Date:  2014-09-16       Impact factor: 2.803

3.  DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo.

Authors:  Saul R Hymes; Tara M Randis; Thomas Yang Sun; Adam J Ratner
Journal:  J Infect Dis       Date:  2013-02-19       Impact factor: 5.226

4.  Influence of age, reproductive cycling status, and menstruation on the vaginal microbiome in baboons (Papio anubis).

Authors:  M Uchihashi; I L Bergin; C M Bassis; S A Hashway; D Chai; J D Bell
Journal:  Am J Primatol       Date:  2015-02-12       Impact factor: 2.371

5.  Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis.

Authors:  Jeanne M Marrazzo; Tina L Fiedler; Sujatha Srinivasan; Katherine K Thomas; Congzhou Liu; Daisy Ko; Hu Xie; Misty Saracino; David N Fredricks
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 6.  Vaginal microbiota and susceptibility to HIV.

Authors:  McKenna C Eastment; R Scott McClelland
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

7.  The Vaginal Microbiome: Current Understanding and Future Directions.

Authors:  David H Martin; Jeanne M Marrazzo
Journal:  J Infect Dis       Date:  2016-08-15       Impact factor: 5.226

8.  Biogenic Amines Increase the Odds of Bacterial Vaginosis and Affect the Growth of and Lactic Acid Production by Vaginal Lactobacillus spp.

Authors:  Joanna-Lynn C Borgogna; Michelle D Shardell; Savannah G Grace; Elisa K Santori; Benjamin Americus; Zhong Li; Alexander Ulanov; Larry Forney; Tiffanie M Nelson; Rebecca M Brotman; Jacques Ravel; Carl J Yeoman
Journal:  Appl Environ Microbiol       Date:  2021-04-27       Impact factor: 4.792

9.  Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure.

Authors:  B Wang; B B Xiao; C G Shang; K Wang; R S Na; X X Nu; Q Liao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-10       Impact factor: 3.267

10.  Primate vaginal microbiomes exhibit species specificity without universal Lactobacillus dominance.

Authors:  Suleyman Yildirim; Carl J Yeoman; Sarath Chandra Janga; Susan M Thomas; Mengfei Ho; Steven R Leigh; Bryan A White; Brenda A Wilson; Rebecca M Stumpf
Journal:  ISME J       Date:  2014-07-18       Impact factor: 10.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.